Navigation Links
Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
Date:12/5/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, December 5 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today that it will present at RBC Capital Markets 2008 Healthcare Conference on Thursday, December 10, from 2:30-3:35 pm EST at the Westin Hotel in New York.

A live audio webcast of the presentation will be available on the "Investors" section of the company's website, http://www.RosettaGenomics.com. A replay of the presentation will be available for 30 days after the conference.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies i
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., ST.LOUIS,Nov.24/PRNewswire-FirstCall/--Sigma-...ttheNASDAQOMXconferenceonTuesday,December1stat1:45...tenvialiveaudiobroadcastovertheInternetavailableat...Userscanclickthe"Webcast"icontoaccessthisfile. ,...ifeScienceandHighTechnologycompany.Itschemicalandb...
(Date:11/24/2009)..., SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/-...ompanyfocusedondevelopingandcommercializingnovelpa...onno,PresidentandChiefExecutiveOfficer,isscheduled...erence,tobeheldDecember1-2,2009atTheNewYorkPalaceH...higlieri,ChiefFinancialOfficer,willbeavailabletore...
(Date:11/24/2009)..., ,Primaryefficacyendpointhasbeenmetforpatientsw..., QUEBECCITY,Nov.24/PRNewswire-FirstCall/-AEter...),aglobalbiopharmaceuticalcompanyfocusedonendocrin...datafromaPhase2studywithitstargetedcytotoxicpeptid...advancedorrecurrentendometrialcancer.Inapersonaliz...
(Date:11/24/2009)..., REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCal...dthatRandyScott,GenomicHealth,sExecutiveChairman,w...ferenceinNewYorkCityonTuesday,December1,2009at10:0...vedwebcastofthepresentation,visittheInvestorRelati...or.genomichealth.com .Pleaseconnecttothewebsiteatl...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...armaceuticals, the proprietary products division o...Companies, Inc. (NYSE: PRX ) today,announced that... Inc.,(Amex: IMM ) has chosen to discontinue the ...nvestigative therapy., On February 22, 2008, Immt...rts of adverse events related to abnormal kidney f...
...agene Inc., a,biotechnology company that develops ... announced today that one of the Nature Research,J...he FACTORIAL(TM). In,advance online publication on...colleagues describes a novel and remarkably consis...tivity of a large panel of transcription,factors.,...
...l/ - Oncothyreon Inc. (Nasdaq,- ONTY) (TSX - ONY) ...f,data demonstrating the effectiveness of PX-478 i...8th Annual Targeted Therapies of the Treatment of,...on for the Study of Lung,Cancer in Santa Monica, C...2008, by Jorg J. Jacoby, Ph.D., Instructor, Univer...
Other Biology Technology:Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 2Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 3Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Oncothyreon's PX-478 is effective in preclinical model of human lung cancer 2Oncothyreon's PX-478 is effective in preclinical model of human lung cancer 3
(Date:11/23/2009)... , CINCINNATINew research presents strong evidenc...sure to both outdoor traffic-related pollution and...ungs than one or the other exposure alone. , E...f Cincinnati (UC) College of Medicine have shown t...c-related particles and indoor endotoxin during ea...
(Date:11/23/2009)... , TORONTO, November 23, 2009 - The time of day...ording to a new paper produced by a research team ...oronto Scarborough,s vice-principal for research a...s biology at the St. George campus. , Capitali...f the poplar tree, the research team examined how ...
(Date:11/23/2009)... , Farmington, CT Current research suggests that... disease. The related report by Nichols et al, "U...nt a New Class of TLR2 Ligands Capable of Enhancin...e of The American Journal of Pathology . , Mult...stem attacks the brain and spinal cord, affects ne...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Diabetes drug kills cancer stem cells in combination treatment in mice 9909 1Diabetes drug kills cancer stem cells in combination treatment in mice 9909 2Diabetes drug kills cancer stem cells in combination treatment in mice 9909 3Alert status area in brain discoved by Hebrew University scientists 9907 1Alert status area in brain discoved by Hebrew University scientists 9907 2Translational Research 3A From Bench to Bedside Capitol Hill Breakfast Briefing Hosted by the Council for American Medical Innovation 57026 1Translational Research 3A From Bench to Bedside Capitol Hill Breakfast Briefing Hosted by the Council for American Medical Innovation 57026 2
...oth pass on "traditions" to other members of their...ng behaviour. The findings add to evidence that cu...e study involved killerwhales at Marineland in Nia...evised a brand new way to catch birds, and passed ...orca lures gulls into his tank by spitting regurgi...
...ribed to patients with the common cold because the...nd the benefits do not outweigh the risks, accordi... , "Antibiotics appear to have no benefit in the t...ns," conclude Dr. Bruce Arroll and Dr. Timothy Ken...The implications for practice are that prescriptio...
...ands of biologists around the globe run DNA sequen...nline algorithm called BLAST ?typically submitting...de, to be matched against the billions of letters ...an shed light on functional or evolutionary relati...hrough and produce vast amounts of data. Everyday ...
Other Biology News:More animals join the learning circle 2Doctors should stop prescribing antibiotics for the common cold, review advises 2Drawing with DNA: 'Bioart' illuminates genomics 2Drawing with DNA: 'Bioart' illuminates genomics 3
...0 contains 400 unique human proteins on a 1x3 inch...a cross section of all cellular proteins, are arra...itional control proteins and a specific chip layou...NIchip protein microarrays are high-density protei...
...0 contains 400 unique human proteins on a 1x3 inch...all extracellular proteins (EP) according to Gene ...ate for high-quality results. Additional control p...validity and reproducibility., UNIchip protein mic...
...s are E.Coli glycerol stocks contained in standard...cDNA clones with approximately 5,000 clones per pl... plate well, the corresponding subplate is screene...ve well(s). Cells from a positive well are then pl...
...ed Reticulocyte Lysate Systems(a,b,c,d) offer rese...nslations: a single-tube, coupled transcription/tr...implify the process and reduce the time required t...bbit reticulocyte lysate translations (1) commonly...
Biology Products: